Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KYMR 
Kymera Therapeutics Inc (KYMR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: KYMR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 48.65% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.64B USD | Price to earnings Ratio - | 1Y Target Price 57.95 |
Price to earnings Ratio - | 1Y Target Price 57.95 | ||
Volume (30-day avg) 705957 | Beta 2.23 | 52 Weeks Range 24.36 - 53.27 | Updated Date 04/1/2025 |
52 Weeks Range 24.36 - 53.27 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.98 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1092.17% |
Management Effectiveness
Return on Assets (TTM) -20.65% | Return on Equity (TTM) -36.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1376538002 | Price to Sales(TTM) 34.82 |
Enterprise Value 1376538002 | Price to Sales(TTM) 34.82 | ||
Enterprise Value to Revenue 29.24 | Enterprise Value to EBITDA -9.49 | Shares Outstanding 64944100 | Shares Floating 42841049 |
Shares Outstanding 64944100 | Shares Floating 42841049 | ||
Percent Insiders 2.49 | Percent Institutions 109.88 |
Analyst Ratings
Rating 4.45 | Target Price 59.11 | Buy 3 | Strong Buy 13 |
Buy 3 | Strong Buy 13 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kymera Therapeutics Inc
Company Overview
History and Background
Kymera Therapeutics Inc. was founded in 2016. It is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins.
Core Business Areas
- Targeted Protein Degradation: Kymera's core business revolves around developing therapeutics based on targeted protein degradation using its proprietary protein degrader platform, Pegasus.
Leadership and Structure
Nello Mainolfi is the President and CEO. The company has a typical biotech organizational structure with research, development, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- KT-474 (SAR444229): An IRAK4 degrader being developed in partnership with Sanofi for atopic dermatitis, hidradenitis suppurativa, and other inflammatory diseases. Clinical trials are ongoing. Revenue is primarily milestone-based from Sanofi. Competitors include JAK inhibitors and biologics targeting inflammatory pathways. Market share and sales figures not available at this time.
- KT-333: A STAT3 degrader in Phase 1 clinical trials for hematologic malignancies and solid tumors. Competitors include other STAT3 inhibitors and standard cancer therapies. Market share and sales figures not available at this time.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and innovative, with a growing focus on targeted therapies. Targeted protein degradation is an emerging field with potential to address previously undruggable targets.
Positioning
Kymera is a leader in the targeted protein degradation field with a proprietary platform and a growing pipeline of drug candidates. Its competitive advantage lies in its expertise in E3 ligase biology and degrader design.
Total Addressable Market (TAM)
The TAM for targeted protein degradation is potentially very large, encompassing a broad range of diseases across oncology, immunology, and other therapeutic areas. Kymera is positioned to capture a significant portion of this market if its clinical programs are successful.
Upturn SWOT Analysis
Strengths
- Proprietary Pegasus platform for targeted protein degradation
- Strong intellectual property portfolio
- Experienced management team
- Partnership with Sanofi for KT-474
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Dependence on partnerships for funding and development
Opportunities
- Expansion of pipeline with new degrader programs
- Potential for partnerships with other pharmaceutical companies
- Successful clinical trials leading to regulatory approvals
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from other companies developing protein degraders
- Regulatory hurdles
- Patent challenges
- Economic downturn affecting funding for biotech companies
Competitors and Market Share
Key Competitors
- ARVN
- CRIS
- VRTX
- REGN
- MRNA
Competitive Landscape
Kymera is a leading player in the targeted protein degradation field, but faces competition from other biotech and pharmaceutical companies developing similar technologies. Its advantage lies in its expertise in E3 ligase biology and degrader design. Key players also include companies developing therapies for related disease indications.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Kymera's growth has been driven by its advancement of degrader programs through preclinical and clinical development and its partnership with Sanofi. Revenue primarily consists of collaboration revenue.
Future Projections: Future growth is dependent on clinical trial success, regulatory approvals, and potential new partnerships. Analyst estimates vary depending on these factors.
Recent Initiatives: Advancement of KT-474 and KT-333 into later-stage clinical trials, expansion of pipeline with new degrader programs, and continued investment in the Pegasus platform.
Summary
Kymera Therapeutics is a clinical-stage biotech company pioneering targeted protein degradation. Its technology holds great promise, but it is high risk. The company has a partnership with Sanofi that provides needed capital to advance the IRAK4 degrading KT-474. Clinical trial successes will be needed to unlock value for the shareholders.
Similar Companies
ARVN
Arvinas Inc
ARVN
Arvinas Inc
CRIS
Curis Inc
CRIS
Curis Inc
MRNA
Moderna Inc
MRNA
Moderna Inc
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
SNY
Sanofi ADR
SNY
Sanofi ADR
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Kymera Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kymera Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-08-21 | Co-Founder, President, CEO & Director Dr. Nello Mainolfi M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 188 | Website https://www.kymeratx.com |
Full time employees 188 | Website https://www.kymeratx.com | ||
Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.